trending Market Intelligence /marketintelligence/en/news-insights/trending/uY4zS8gHVHP-3tkLcXxY0g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Generex Biotechnology to spin out subsidiary into new public company

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Generex Biotechnology to spin out subsidiary into new public company

Generex Biotechnology Corp. plans to spin out its subsidiary, NuGenerex Immuno-Oncology, as a separate publicly traded company.

Miramar, Fla.-based Generex said it would issue one or more dividends of NuGenerex Immuno-Oncology shares to its stockholders under the spinout and intends to retain a controlling interest in the new company.

According to a Jan. 4 press release, Generex will seek to list the new company on a national stock exchange.

Generex expects the spinout, which is subject to market conditions and regulatory requirements, to be completed after the annual meeting of its stockholders.

The biotechnology company is searching for candidates for NuGenerex Immuno-Oncology's board and executive team.